Trends in adult antipsychotic polypharmacy: Progress and challenges in florida's medicaid program

Community Mental Health Journal

Volumn 46, Issue 6, 2010, Pages 523-530

  Constantine, Robert J ^c   Andel, Ross ^a   Tandon, Rajiv ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c NONE

Author keywords

Antipsychotic; Quality improvement; Trends

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL PRACTICE; DRUG UTILIZATION; FEMALE; HUMAN; MALE; MEDICAID; MIDDLE AGED; POLYPHARMACY; PSYCHOSIS; RETROSPECTIVE STUDY; STATISTICS; TOTAL QUALITY MANAGEMENT; UNITED STATES;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DRUG UTILIZATION; FEMALE; FLORIDA; HUMANS; MALE; MEDICAID; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; PSYCHOTIC DISORDERS; QUALITY IMPROVEMENT; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 78649331683     PISSN: 00103853     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10597-009-9288-2     Document Type: Article

References (47)

1. American Psychiatric Association 2004 Practice guidelines for the treatment of patients with schizophrenia American Journal of Psychiatry 161 Supplement 1 56
2. C Barbui M Nose MA Mazzi G Thornicroft A Schene T Becker J Bindman M Leese H Helm M Koeter S Weinmann M Tansella 2006 Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries International Clinical Psychopharmacology 21 6 355 362 10.1097/01.yic.0000224785.68040.43 17012982 (Pubitemid 44498277)
3. B Biancosino C Barbui L Marmai S Doná L Grassi 2005 Determinants of antipsychotic polypharmacy in psychiatric inpatients: A prospective study International Clinical Psychopharmacology 20 6 305 309 10.1097/00004850- 200511000-00004 16192838 (Pubitemid 41475319)
4. WJ Broekema IW de Groot PN van Harten 2007 Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study Pharmacy World & Science 29 3 126 130 1:STN:280: DC%2BD2szjtl2mtA%3D%3D 10.1007/s11096-006-9063-1 (Pubitemid 46872979)
5. Center for Medicare Advocacy. (2008). http://www.medicareadvocacy.org.
6. F Centorrino JL Goren J Hennen P Salvatore JP Kelleher RJ Baldessarini 2004 Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits American Journal of Psychiatry 161 4 700 706 10.1176/appi.ajp.161.4.700 15056517 (Pubitemid 38445515)
7. MH Chakos ID Glick AL Miller MB Hamner DD Miller JK Patel A Tapp RSE Keefe RA Rosenheck 2006 Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE Trial Psychiatric Services 57 8 1094 1101 10.1176/appi.ps.57.8.1094 16870959 (Pubitemid 44204901)
8. RE Clark SJ Bartels TA Mellman WJ Peacock 2002 Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorders: Implications for state mental health policy Schizophrenia Bulletin 28 1 75 84 12047024
9. Clinical practice guidelines. (2005). Treatment of schizophrenia. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, 50:(13 Suppl 1), 7S-57S.
10. RJ Constantine S Richard R Surlea, et al. 2006 Optimizing pharmacotherapy of schizophrenia: Tools for the psychiatrist Current Psychosis and Therapeutics Reports 4 1 5 11 10.1007/BF02629408 (Pubitemid 44623832)
11. CU Correll 2008 Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment? American Society of Clinical Psychopharmacology 69 4 674 675
12. Elie, D., Poirier, M., Chianetta, J., Durand, M., Gregoire, C., & Grignon, S. (2009). Cognitive effects of antipsychotic dosage and polypharmacy: A study with the BACS in patients with schizophrenia and schizoaffective disorder. Journal of Psychopharmacology, 1-8.
13. D Faries H Ascher-Svanum B Zhu C Correll J Kane 2005 Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics BMC Psychiatry [Electronic Resource] 5 1 26 10.1186/1471-244X-5-26 (Pubitemid 41460700)
14. Florida Schizophrenia Guidelines. (2005). http://flmedicaidbh.fmhi.usf. edu/index.htm.
15. O Freudenreich DC Goff 2002 Antipsychotic combination therapy in schizophrenia: A review of efficacy and risks of current combinations Acta Psychiatrica Scandinavica 106 5 323 330 1:CAS:528:DC%2BD38XoslyiurY%3D 10.1034/j.1600-0447.2002.01331.x 12366465 (Pubitemid 35176874)
16. S Ganesan R Taylor K Rabheru I Forbes J Dumontet RM Procyshyn 2008 Antipsychotic polypharmacy does not increase the risk for side effects Schizophrenia Research 98 1 323 324 10.1016/j.schres.2007.09.002 17950576 (Pubitemid 350245589)
17. R Ganguly JA Kotzan LS Miller K Kennedy BC Martin 2004 Prevalence, trends, and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998-2000 The Journal of Clinical Psychiatry 65 10 1377 1388 10.4088/JCP.v65n1013 15491242
18. TP Gilmer CR Dolder DP Folsom W Mastin DV Jeste 2007 Antipsychotic polypharmacy trends among medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004 Psychiatric Services 58 7 1007 1010 10.1176/appi.ps.58.7.1007 17602020 (Pubitemid 47122882)
19. DC Goff O Freudenreich 2004 Focus on polypharmacy in schizophrenia: does anyone truly benefit? The International Journal of Neuropsychopharmacology/ Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 7 2 109 111
20. JL Goren JJ Parks FA Ghinassi CG Milton JM Oldham P Hernandez J Chan RC Hermann 2008 When is antipsychotic polypharmacy supported by research evidence? Implications for QI Joint Commission Journal on Quality and Patient Safety 34 10 571 582 18947117
21. Hardin, J., & Hilbe, J. (2002). Generalized estimating equations. Danvers, MA: CRC Press.
22. Hori, H., Noguchi, H., Hashimoto, R., Nakabayashi, T., Omori, M., Takahashi, S., Tsukue, R., Anami, K., Hirabayashi, N., Harada, S., Saitoh, O., Iwase, M., Kajimoto, O., Takeda, M., Okabe, S., & Kunugi, H. (2006). Antipsychotic medication and cognitive function in schizophrenia.
23. H Ito A Koyama T Higuchi 2005 Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription The British Journal of Psychiatry: The Journal of Mental Science 187 243 247 10.1192/bjp.187.3.243 (Pubitemid 41306105)
24. M Joukamaa M Heliovaara P Knekt A Aromaa R Raitasalo V Lehtinen 2006 Schizophrenia, neuroleptic medication and mortality British Journal of Psychiatry 188 2 122 127 10.1192/bjp.188.2.122 16449697 (Pubitemid 43171066)
25. J Kreyenbuhl M Valenstein JF McCarthy D Ganoczy FC Blow 2006 Long-term combination antipsychotic treatment in VA patients with schizophrenia Schizophrenia Research 84 1 90 99 10.1016/j.schres.2006.02.023 16631354 (Pubitemid 43732483)
26. P Lelliott C Paton M Harrington M Konsolaki T Sensky C Okocha 2002 The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients Psychiatric Bulletin 26 11 411 414 10.1192/pb.26.11.411 (Pubitemid 35331237)
27. SBTDL Lewis, et al. 2006 Randomized controlled trial of effect of prescription of clozapine verses other second-generation antipsychotic drugs in treatment resistant schizophrenia Schizophrenis Bulletin 32 4 715 723 10.1093/schbul/sbj067 (Pubitemid 44412859)
28. DL Loosbrock Z Zhao BM Johnstone LS Morris 2003 Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia The Journal of Mental Health Policy and Economics 6 2 67 75 14578539
29. RE McCue R Waheed L Urcuyo 2003 Polypharmacy in patients with schizophrenia The Journal of Clinical Psychiatry 64 9 984 989 10.4088/JCP.v64n0902 14628972
30. JP McEvoy JM Meyer DC Goff HA Nasrallah SM Davis L Sullivan HY Meltzer J Hsiao T Scott Stroup JA Lieberman 2005 Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III Schizophrenia Research 80 1 19 32 10.1016/j.schres.2005.07.014 16137860 (Pubitemid 41587460)
31. AL Miller CS Craig 2002 Combination antipsychotics: pros, cons, and questions Schizophrenia Bulletin 28 1 105 109 12047009
32. EH Morrato S Dodd G Oderda DG Haxby R Allen RJ Valuck 2007 Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: Experience in a Multistate medicaid population, 1998-2003 Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy 29 1 183 195 1:CAS:528:DC%2BD2sXjsVOns7g%3D
33. National Institute for Clinical Excellence. (2002). Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care: Clinical Guideline 1.
34. RM Procyshyn NB Kennedy G Tse B Thompson 2001 Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care psychiatric institution The Canadian Journal of Psychiatry/La Revue Canadienne De Psychiatrie 46 4 334 339 1:STN:280:DC%2BD3MzhsFKgtA%3D%3D
35. AJ Rush ML Crismon TM Kashner MG Toprac TJ Carmody MH Trivedi T Suppes AL Miller MM Biggs K Shores-Wilson BP Witte SP Shon WV Rago KZ Altshuler 2003 Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design The Journal of Clinical Psychiatry 64 4 357 369 10.4088/JCP.v64n0402 12716235
36. MJ Sernyak R Rosenheck 2004 Clinicians' reasons for antipsychotic coprescribing Journal of Clinical Psychiatry 65 12 1597 1600 10.4088/JCP.v65n1203 15641863
37. K Sim A Su S Fujii SY Yang MY Chong GS Ungvari T Si EK Chung HY Tsang YH Chan S Heckers N Shinfuku CH Tan 2004 Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia British Journal of Clinical Pharmacology 58 2 178 183 10.1111/j.1365-2125.2004.02102.x 15255800 (Pubitemid 39043998)
38. SM Stahl 2004 Focus on Antipsychotic polypharmacy: Evidence-based prescribing or prescribing-based evidence? International Journal of Neuropsychopharmacology 7 2 113 116 10.1017/S1461145704004146 14984629 (Pubitemid 38823277)
39. T Suzuki H Uchida KF Tanaka M Tomita K Tsunoda K Nomura H Takano A Tanabe K Watanabe G Yagi H Kashima 2003 Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia International Clinical Psychopharmacology 18 6 323 329 10.1097/00004850-200311000-00003 14571152 (Pubitemid 38183485)
40. T Suzuki H Uchida K Watanabe S Nakajima K Nomura H Takeuchi A Tanabe G Yagi H Kashima 2008 Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: An open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone Human Psychopharmacology: Clinical and Experimental 23 6 455 463 1:CAS:528:DC%2BD1cXhtFSlurzP 10.1002/hup.959
41. A Tapp 2003 Combination antipsychotic therapy in clinical practice Psychiatric Services 54 4 574a 10.1176/appi.ps.54.4.574-a
42. C Tranulis 2008 Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature Drug Safety 31 1 7 20 1:CAS:528:DC%2BD1cXisFCit7s%3D 10.2165/00002018-200831010-00002 18095743
43. U.S. Food and Drug Administration: Center for Drug Evaluation and Research. (2007). National drug code directory. http://www.fda.gov/cder/ndc/ database/default.htm.
44. RJ Valuck EH Morrato S Dodd G Oderda DG Haxby R Allen 2007 How expensive is antipsychotic polypharmacy? Experience from five US state medicaid programs Current Medical Research and Opinion 23 10 2567 2576 10.1185/030079907X233214 17848204 (Pubitemid 350033459)
45. JL Waddington HA Youssef A Kinsella 1998 Mortality in schizophrenia: Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study British Journal of Psychiatry 173 325 329 1:STN:280:DyaK1M7isVylsg%3D%3D 10.1192/bjp.173.4.325 9926037
46. EM Weissman 2002 Antipsychotic prescribing practices in the veterans healthcare administration-New York metropolitan region Schizophrenia Bulletin 28 1 31 42 12047020
47. B Zhu H Ascher-Svanum DE Faries CU Correll JM Kane 2008 Cost of antipsychotic polypharmacy in the treatment of schizophrenia BMC Psychiatry 8 19 10.1186/1471-244X-8-19 18394168 (Pubitemid 351622429)